PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Clinical trials for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) explained in plain language.
Never miss a new study
Get alerted when new PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC) trials appear
Sign up with your email to follow new studies for PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New hope for hard-to-treat pancreatic cancer: combo therapy targets genetic weak spot
Disease control Recruiting nowThis study tests a combination of an immunotherapy drug (cemiplimab) and chemotherapy (gemcitabine) in people with advanced pancreatic cancer that has a specific genetic change (SWI/SNF). The goal is to see if this combo helps patients live longer. About 43 adults who have alread…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Phase: PHASE2 • Sponsor: University of California, San Diego • Aim: Disease control
Last updated May 26, 2026 09:02 UTC
-
New drug trial targets Hard-to-Treat stomach and pancreatic cancers
Disease control Recruiting nowThis early-stage trial tests a new drug called DA 3501 in adults with advanced stomach or pancreatic cancer that has a specific marker (CLDN18.2). The main goals are to find the safest dose and see if the drug can shrink tumors. Participants receive the drug every three weeks and…
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Phase: PHASE1 • Sponsor: Dong-A ST Co., Ltd. • Aim: Disease control
Last updated May 26, 2026 08:33 UTC
-
Blood marker may predict deadly pancreatic surgery complications
Knowledge-focused Recruiting nowThis study is looking at whether a blood test measuring mHLA-DR can help predict severe complications after pancreatic surgery. The researchers will follow 100 adults who are having this surgery to see if low mHLA-DR levels are linked to problems like infection or organ failure. …
Matched conditions: PANCREATIC DUCTAL ADENOCARCINOMA (MPDAC)
Sponsor: Hospices Civils de Lyon • Aim: Knowledge-focused
Last updated May 26, 2026 09:02 UTC